Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000077850 | DOI Listing |
JAAD Int
April 2025
Department of Dermatology, Nara Medical University School of Medicine, Nara, Japan.
Front Immunol
March 2025
Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Apalutamide, an androgen receptor inhibitor, has shown good efficacy in treating prostate cancer (PCa). However, dermatological adverse events (dAEs) are common and threatening, and relevant studies in China are limited.
Methods: This was a retrospective, single-center analysis.
Sci Rep
March 2025
Department of Dental Surgery, Periodontology and Oral Mucosa Diseases, Poznań University of Medical Sciences, 70 Bukowska Street, Poznań, 60-812, Poland.
The number of allogeneic hematopoietic cell transplantation constantly increases. Therefore, there is an urgent need to carefully analyze the general and oral health state of people with acute myeloid leukemia who underwent this procedure. This study aimed to investigate the type and frequency of oral mucosal lesions in patients with acute myeloid leukemia after allogeneic hematopoietic cell transplantation, depending on the intensity of the conditioning regimen.
View Article and Find Full Text PDFBMC Oral Health
February 2025
Department of Orthodontics and Pediatric Dentistry, College of Dentistry, Qassim University, Buraydah, 52571, Saudi Arabia.
Background: Evidence on the association between early tooth eruption and a high incidence of dental caries is scarce and mixed. Therefore, this study aimed to assess the relationship between the timing of tooth eruption and development of dental caries in 229 children from six dental clinics in Qassim, Saudi Arabia.
Methods: This was a descriptive, cross-sectional study involving 229 children from six dental clinics in Qassim, Saudi Arabia.
Arch Dermatol Res
February 2025
Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China.
In January 2022, the U.S. Food and Drug Administration (FDA) approved the marketing of abrocitinib, an oral small molecule selectively inhibiting Janus kinase, for the treatment of patients with recurrent moderate to severe atopic dermatitis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!